Bristol OTC Stock Leadership


USD 1,101  0.00  0.00%   

Bristol Myer employes about 23.7 K people. The company is managed by 34 executives with total tenure of roughly 223 years, averaging almost 6.0 years of service per executive having 697.06 employees per reported executive. Analysis of Bristol Myer management performance can provide insight into the firm performance. Note, employee sentiment is becoming a valuable factor that investors use to determine the amount of risk that may be associated with Bristol Myer Squi future performance.
Continue to Trending Equities.
  Lamberto Andreotti  CEO
CEO, Director
  Ann Powell  President
Chief Human Resource Officer, Senior Vice President
  Adam Dubow  President
Senior Vice President Chief Compliance Officer and Ethics Officer

Bristol Myer Management Team Effectiveness

Bristol Myer Squi has return on total asset (ROA) of 10.68 % which means that it generated profit of $10.68 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on equity (ROE) of 2.97 %, meaning that it generated $2.97 on every $100 dollars invested by stockholders. Bristol Myer management efficiency ratios could be used to measure how well the company manages its routine affairs as well as how well it operates its assets and liabilities.

Bristol Myer Workforce Comparison

Bristol Myer Squi is rated below average in number of employees category among related companies. The total workforce of Drug Manufacturers - Major industry is currently estimated at about 948,300. Bristol Myer holds roughly 23,700 in number of employees claiming about 2.5% of equities under Drug Manufacturers - Major industry.

Bristol Myer Profit Margins

The company has Profit Margin (PM) of 1.74 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 26.12 %, which suggests for every 100 dollars of sales, it generated a net operating income of 0.26.

Bristol Myer Squi Benchmark Summation

The output start index for this execution was zero with a total number of output elements of sixty-one. Bristol Myer Squi Price Series Summation is a cross summation of Bristol Myer price series and its benchmark/peer.

Bristol Myer Notable Stakeholders

A Bristol Myer stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Bristol Myer often face trade-offs trying to please all of them. Bristol Myer's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Bristol Myer's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Lamberto Andreotti - CEO, DirectorProfile
Ann Powell - Chief Human Resource Officer, Senior Vice PresidentProfile
Adam Dubow - Senior Vice President Chief Compliance Officer and Ethics OfficerProfile
Charles Bancroft - CFO, Executive Vice PresidentProfile
Louis Schmukler - President - Global Manufacturing and SupplyProfile
Christopher Boerner - Executive Vice President and Chief Commercial OfficerProfile
John Elicker - Senior Vice President - Public Affairs and Investor RelationsProfile
Anne Nielsen - Senior Vice President Chief Compliance and Ethics OfficerProfile
Karen Santiago - Senior Vice President ControllerProfile
Emmanuel Blin - Senior Vice President Chief Strategy OfficerProfile
Joseph Caldarella - Senior Vice President Corporate ControllerProfile
Murdo Gordon - Executive Vice President Chief Commercial OfficerProfile
Samuel Moed - Senior Vice President - Strategic Planning and AnalysisProfile
Ann Judge - Senior Vice President - Global Human ResourcesProfile
Paul Autenried - Senior Vice President - Enterprise Services, CIOProfile
Francis Cuss - Executive Vice President Chief Scientific OfficerProfile
Paul Biondi - Senior Vice President Head - Business DevelopmentProfile
Togo West - Independent DirectorProfile
Karen Vousden - DirectorProfile
Alan Lacy - Independent DirectorProfile
Robert Bertolini - Independent DirectorProfile
Jose Baselga - Independent DirectorProfile
Gerald Storch - Independent DirectorProfile
Michael Grobstein - Independent DirectorProfile
Giovanni Caforio - COO, DirectorProfile
Vicki Sato - Independent DirectorProfile
Laurie Glimcher - Independent DirectorProfile
Thomas Lynch - Independent DirectorProfile
Dinesh Paliwal - Independent DirectorProfile
Lewis Campbell - Independent DirectorProfile
Theodore Samuels - Independent DirectorProfile
Matthew Emmens - Independent DirectorProfile
Peter Arduini - Independent DirectorProfile
Sandra Leung - General Counsel, Corporate SecretaryProfile

About Bristol Myer Management Performance

The success or failure of an entity such as Bristol Myer Squi often depends on how effective the management is. Bristol Myer management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Bristol management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Bristol management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Please read more on our stock advisor page.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug Manufacturers - Major classification in USA and is traded on OTC Market. It employs 23700 people.
The data published in Bristol Myer's official financial statements usually reflect Bristol Myer's business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Bristol Myer Squi. For example, before you start analyzing numbers published by Bristol accountants, it's critical to develop an understanding of what Bristol Myer's liquidity, profitability, and earnings quality are in the context of the Healthcare space in which it operates.
Please note, the presentation of Bristol Myer's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Bristol Myer's management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Bristol Myer's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Bristol Myer Squi. Please utilize our Beneish M Score to check the likelihood of Bristol Myer's management to manipulate its earnings.

Bristol Myer Workforce Analysis

Traditionally, organizations such as Bristol Myer use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Bristol Myer within its industry.

Bristol Myer Manpower Efficiency

Return on Bristol Myer Manpower

Revenue Per Employee911.4 K
Revenue Per Executive635.3 M
Net Income Per Employee15.9 K
Net Income Per Executive11.1 M
Continue to Trending Equities. Note that the Bristol Myer Squi information on this page should be used as a complementary analysis to other Bristol Myer's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.

Complementary Tools for Bristol OTC Stock analysis

When running Bristol Myer Squi price analysis, check to measure Bristol Myer's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myer is operating at the current time. Most of Bristol Myer's value examination focuses on studying past and present price action to predict the probability of Bristol Myer's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bristol Myer's price. Additionally, you may evaluate how the addition of Bristol Myer to your portfolios can decrease your overall portfolio volatility.
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Is Bristol Myer's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myer. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myer listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Bristol Myer Squi is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myer's value that differs from its market value or its book value, called intrinsic value, which is Bristol Myer's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myer's market value can be influenced by many factors that don't directly affect Bristol Myer's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol Myer's value and its price as these two are different measures arrived at by different means. Investors typically determine Bristol Myer value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myer's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.